法属波利尼西亚的痛风流行:基于Ma'i u'u流行病学调查数据的建模研究
该前瞻性横断面调查随机抽取法属波利尼西亚成人,估算痛风患病率为14.5%(95%CI 9.9-19.2),高尿酸血症患病率为71.6%(66.7-76.6),并分析痛风与年龄、男性、血尿酸、尿尿酸、2型糖尿病、BMI及内脏脂肪百分比的关联,HLA-B*58:01等位基因频率低。作者认为需采取领土层面措施增加有效降尿酸治疗的可及性。
要点
- 痛风患病率为14.5%(95%CI 9.9-19.2),相当于28561名成人。
- 高尿酸血症患病率为71.6%(95%CI 66.7-76.6),相当于128687名成人。
- 男性痛风患病率25.5%(95%CI 18.2-32.8)高于女性3.5%(95%CI 1.0-6.0)。
核心结论
- 法属波利尼西亚痛风和高尿酸血症估计患病率高,痛风影响近15%成人。
- 作者认为有必要采取领土层面措施,重点增加有效降尿酸治疗的可及性,以控制这一重大公共卫生问题。
研究设计与样本
- Ma'i u'u调查为流行病学、前瞻性、横断面、以痛风为重点的研究,于2021年4月13日至8月16日期间进行并收集数据。
- 基于2017年领土普查的住房数据随机抽取法属波利尼西亚普通成人人群,最终加权分析纳入874名参与者(女性449名[51.4%],男性425名[48.6%]),代表196630名成人。
- 随机样本为2000户,896名参与者纳入,140人拒绝,964户无法联系,22名参与者因数据缺失无法加权。
- 通过全基因组测序(约5×平均覆盖度,mid-pass测序)估计HLA-B单倍型,并利用自我报告波利尼西亚血统且无欧洲、中国或其他血统的子集估计波利尼西亚血统特异性等位基因频率。
- 双变量关联在加权参与者中报告,效应量通过基于加权观测拟合的逻辑模型计算的比值比(OR)估计。
主要发现
- 痛风估计患病率为14.5%(95%CI 9.9-19.2),相当于28561名法属波利尼西亚成人;男性为25.5%(95%CI 18.2-32.8),女性为3.5%(95%CI 1.0-6.0)。
- 高尿酸血症估计患病率为71.6%(95%CI 66.7-76.6),相当于128687名法属波利尼西亚成人。
- 多变量分析中,与痛风相关的因素包括:年龄(每岁OR 1.5,95%CI 1.2-1.8)、男性(OR 10.3,95%CI 1.8-60.7)、血清尿酸(每1 mg/dL OR 1.6,95%CI 1.3-2.0)、尿尿酸(每100 mg/L OR 0.8,95%CI 0.8-0.8)、2型糖尿病(OR 2.1,95%CI 1.4-3.1)、BMI超过30 kg/m2(每单位OR 1.1,95%CI 1.0-1.2)、内脏脂肪百分比(每增加1% OR 1.7,95%CI 1.1-2.7)。
- 在833名个体的完整队列中,有7名杂合HLA-B*58:01携带者(7/1666总等位基因,0.4%);在696名波利尼西亚血统个体的子集中,有2名杂合携带者(2[0.1%])。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gout is the most common cause of inflammatory arthritis worldwide, particularly in Pacific regions. We aimed to establish the prevalence of gout and hyperuricaemia in French Polynesia, their associations with dietary habits, their comorbidities, the prevalence of the HLA-B*58:01 allele, and current management of the disease. METHODS: The Ma'i u'u survey was epidemiological, prospective, cross-sectional, and gout-focused and included a random sample of adults from the general adult population of French Polynesia. It was conducted and data were collected between April 13 and Aug 16, 2021. Participants were randomly selected to represent the general adult population of French Polynesia on the basis of housing data collected during the 2017 territorial census. Each selected household was visited by a research nurse from the Ma'i u'u survey who collected data via guided, 1-h interviews with participants. In each household, the participant was the individual older than 18 years with the closest upcoming birthday. To estimate the frequency of HLA-B*58:01, we estimated HLA-B haplotypes on individuals who had whole-genome sequencing to approximately 5× average coverage (mid-pass sequencing). A subset of individuals who self-reported Polynesian ancestry and not European, Chinese, or other ancestry were used to estimate Polynesian-ancestry specific allele frequencies. Bivariate associations were reported for weighted participants; effect sizes were estimated through the odds ratio (OR) of the association calculated on the basis of a logistic model fitted with weighted observations. FINDINGS: Among the random sample of 2000 households, 896 participants were included, 140 individuals declined, and 964 households could not be contacted. 22 participants could not be weighted due to missing data, so the final weighted analysis included 874 participants (449 [51·4%] were female and 425 [48·6%] were male) representing the 196 630 adults living in French Polynesia. The estimated prevalence of gout was 14·5% (95% CI 9·9-19·2), representing 28 561 French Polynesian adults, that is 25·5% (18·2-32·8) of male individuals and 3·5% (1·0-6·0) of female individuals. The prevalence of hyperuricaemia was estimated at 71·6% (66·7-76·6), representing 128 687 French Polynesian adults. In multivariable analysis, age (OR 1·5, 95% CI 1·2-1·8 per year), male sex (10·3, 1·8-60·7), serum urate (1·6, 1·3-2·0 per 1 mg/dL), uraturia (0·8, 0·8-0·8 per 100 mg/L), type 2 diabetes (2·1, 1·4-3·1), BMI more than 30 kg/m2 (1·1, 1·0-1·2 per unit), and percentage of visceral fat (1·7, 1·1-2·7 per 1% increase) were associated with gout. There were seven heterozygous HLA-B*58:01 carriers in the full cohort of 833 individuals (seven [0·4%] of 1666 total alleles) and two heterozygous carriers in a subset of 696 individuals of Polynesian ancestry (two [0·1%]). INTERPRETATION: French Polynesia has an estimated high prevalence of gout and hyperuricaemia, with gout affecting almost 15% of adults. Territorial measures that focus on increasing access to effective urate-lowering therapies are warranted to control this major public health problem. FUNDING: Variant Bio, the French Polynesian Health Administration, Lille Catholic University Hospitals, French Society of Rheumatology, and Novartis.
引用
- Pascart T, Wasik KA, Preda C, et al. The gout epidemic in French Polynesia: a modelling study of data from the Ma'i u'u epidemiological survey. Lancet Glob Health. 2024. PMID: 38485432. doi:10.1016/S2214-109X(24)00012-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。